Annals of Surgical Oncology

, Volume 22, Supplement 3, pp 873–879 | Cite as

Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy

  • Véronique Kemmel
  • Henri-Alexis Mercoli
  • Nicolas Meyer
  • Daniel Brumaru
  • Benoit Romain
  • Jean-Marc Lessinger
  • Cécile Brigand
Gastrointestinal Oncology



Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an approach to overcome peritoneal carcinomatosis from colorectal adenocarcinoma. Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia. Our study explores the clinical and surgical risk factors of neutropenia and a possible link between MMC pharmacokinetics and neutropenia as HIPEC’s supervention.


A total of 45 patients undergoing CRS-HIPEC for peritoneal carcinomatosis of colorectal origin between 2004 and 2010 were followed. For each patient, MMC was measured in plasma at different times during HIPEC and the area under the MMC concentration–time curve (MMC-AUC) was calculated.


The incidence of neutropenia was 40 %. No demographic, clinical, or surgical factors increased the risk of neutropenia. However, we found that the occurrence of neutropenia and its gravity increased in direct correlation with an increase in MMC plasma concentration 30 min (T30) and 45 min (T45) after the start of HIPEC. The same correlation was observed between the MMC-AUC and the risk of neutropenia.


Neutropenia is a frequent complication associated with MMC-HIPEC. The results of our study indicate the feasibility and the potential benefit of a protocol including the MMC dosage at T30 after the start of HIPEC. A threshold of 572 µg/L gives a predictive sensitivity of 86 % and a specificity of 80 %. These results must be considered in the management of patients undergoing MMC-HIPEC in order to place high-risk patients under neutropenic monitoring while the other patients can undergo simple hematological monitoring.


Neutropenia Peritoneal Dissemination Severe Neutropenia Complete Cytoreduction Hyperthermic Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors want to thank Christian Ledunois, Muriel Jung, and Marie Rose Carle for their technical assistance and Dr. Maes for his English writing assistance.


  1. 1.
    Hompes D, D’Hoore A, Wolthuis A, et al. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2013;109:527–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21:1501–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart JH 4th, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Butterworth SA, Panton ON, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei. Am J Surg. 2002;183:529–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Lambert LA, Armstrong TS, Lee JJ, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16:2181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRefGoogle Scholar
  8. 8.
    an TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Schnake KJ, Sugarbaker PH, Yoo D. Neutropenia following perioperative intraperitoneal chemotherapy. Tumori. 1999;85:41–6.PubMedGoogle Scholar
  10. 10.
    Lopez-Basave HN, Morales-Vasquez F, Ruiz Molina JM, et al. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico. ISRN Oncol. 2011;2011:526384.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lopez-Basave HN, Morales-Vasquez F, Mendez-Herrera C, et al. Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary? J Oncol. 2014;2014:307317.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bidus MA, Krivak TC, Howard R, et al. Hematologic changes after splenectomy for cytoreduction: implications for predicting infection and effects on chemotherapy. Int J Gynecol Cancer. 2006;16:1957–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179:e133–9.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cotte E, Passot G, Tod M, et al. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18:2599–603.PubMedCrossRefGoogle Scholar
  18. 18.
    Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703–8.PubMedCrossRefGoogle Scholar
  19. 19.
    National Cancer Institut N. Guidance on CTC terminology applications., October 2012.
  20. 20.
    Barbhaiya RH, Papp EA, Van Harken DR, Smyth RD. Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay. J Pharm Sci. 1984;73:1220–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei–a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90.PubMedCrossRefGoogle Scholar
  22. 22.
    van Ruth S, Mathot RA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FA. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43:131–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Becher RD, Shen P, Stewart JH, Russell G, Bradley JF, Levine EA. Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2011;2:70–6.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 2001;54:214–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012;2012:471205.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Véronique Kemmel
    • 1
    • 2
  • Henri-Alexis Mercoli
    • 3
  • Nicolas Meyer
    • 4
    • 5
  • Daniel Brumaru
    • 1
  • Benoit Romain
    • 3
  • Jean-Marc Lessinger
    • 1
  • Cécile Brigand
    • 3
  1. 1.Laboratoire de Biochimie et Biologie MoléculaireHôpitaux Universitaire de StrasbourgStrasbourgFrance
  2. 2.Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U-1119Université de StrasbourgStrasbourgFrance
  3. 3.Service de Chirurgie Générale et DigestiveHôpitaux Universitaire de StrasbourgStrasbourgFrance
  4. 4.Faculté de médecineLaboratoire de BiostatistiquesStrasbourgFrance
  5. 5.Service de Santé PubliqueHôpitaux Universitaire de StrasbourgStrasbourgFrance

Personalised recommendations